JP2019515870A - Antiviral compositions and methods - Google Patents
Antiviral compositions and methods Download PDFInfo
- Publication number
- JP2019515870A JP2019515870A JP2017541381A JP2017541381A JP2019515870A JP 2019515870 A JP2019515870 A JP 2019515870A JP 2017541381 A JP2017541381 A JP 2017541381A JP 2017541381 A JP2017541381 A JP 2017541381A JP 2019515870 A JP2019515870 A JP 2019515870A
- Authority
- JP
- Japan
- Prior art keywords
- antiviral composition
- composition according
- antiviral
- silver
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
銀含有物質、例えば、コロイド銀、硝酸銀、またはこれらの組合せなど、Ｒｕｔａ ｇｒａｖｅｏｌｅｎｓなどのＲｕｔａｃｅａｅ科、Ｍｅｌａｌｅｕｃａ ａｌｔｅｒｎｉｆｏｌｉａなどのＭｙｒｔａｃｅａｅ科、Ｔｈｕｊａ ｏｃｃｉｄｅｎｔａｌｉｓなどのＣｕｐｒｅｓｓａｃｅａｅ科、イチジクなどのＭｏｒａｃｅａｅ科、またはこれらの任意の組合せ由来の抗ウイルス性天然ハーブまたは天然ハーブ、および赤酢などの酢を含む、ウイルス状態を処置する抗ウイルス性組成物および方法。
【選択図】なしSilver-containing materials, eg, colloidal silver, silver nitrate, or combinations thereof, Rutaceae, such as Ruta graveolens, Myrtaceae, such as Melaleuca alternifolia, Cupressaceae, such as Thuja occidentalis, Moreaceae, such as figs, or any combination thereof Antiviral compositions and methods for treating viral conditions, including antiviral natural herbs or natural herbs derived from and vinegar such as red vinegar.
【Selection chart】 None
Description
[0001]本発明は、ウイルス状態を処置するための組成物および方法に関する。 FIELD [0001] The present invention relates to compositions and methods for treating viral conditions.
[0002]ウイルスは、長く地球上の住民を苦しめており、単純から重度の不快（例えば、疣贅、ＨＰＶ、ヘルペス、および帯状疱疹）から死（例えば、ＨＩＶおよびがん）に及ぶ状態をもたらしている。細菌および真菌感染と異なり、ウイルス感染症は、ウイルス遺伝物質の宿主細胞内への注入を伴うという事実に部分的に起因して、かつ部分的に、ウイルスの突然変異する能力のために、処置するのが困難であることが証明されている。 [0002] Viruses have long plagued the Earth's population, resulting in conditions ranging from simple to severe discomfort (eg, warts, HPV, herpes, and shingles) to death (eg, HIV and cancer) ing. Unlike bacterial and fungal infections, viral infections are treated partly due to the fact that they involve the injection of viral genetic material into host cells, and partly because of the ability of the virus to mutate. It has proven to be difficult to do.
[0003]技術および科学的研究の進歩にもかかわらず、病原体、例えば、ウイルス、細菌、真菌、および他の微生物などは、疾患、障害、および機能不全を引き起こし続けている。現在の処置は、無効力および／または望ましくない副作用に苦労している。１人の患者に有効である処置は、別の患者に有効でないことが多い。したがって科学者および医師は、より有効であり、より毒性が低く、容易に生産される新しい処置および薬物を絶えず探求している。 [0003] Despite advances in technology and scientific research, pathogens such as viruses, bacteria, fungi, and other microbes continue to cause disease, disorders, and dysfunction. Current treatments suffer from ineffectiveness and / or undesirable side effects. A treatment that is effective for one patient is often not effective for another patient. Scientists and physicians are therefore constantly searching for new treatments and drugs that are more effective, less toxic and easily produced.
[0004]本発明は、とりわけ、銀含有物質、例えば、コロイド銀、硝酸銀、他の銀誘導体、またはこれらのいくつかの組合せなど、赤酢、および１種または複数の抗ウイルス性天然ハーブ、例えば、イチジク、未熟イチジク、またはイチジク乳液などを含む、ウイルス感染症を処置するための抗ウイルス性組成物および方法を対象とする。 [0004] The present invention provides, inter alia, silver containing materials such as colloidal silver, silver nitrate, other silver derivatives, or some combination thereof, red vinegar, and one or more antiviral natural herbs, for example The present invention is directed to antiviral compositions and methods for treating viral infections, including figs, immature figs, or fig milk and the like.
[0005]添付の図面に関連して以下に示す詳細な説明は、本発明の現在好適な実施形態の記載として意図されており、本発明が構築または利用され得る唯一の形態を代表するように意図されていない。同じまたは等価な機能および組成物を、異なる実施形態によって達成することができることが理解されるべきであり、これらの実施形態も、本発明の趣旨および射程内に包含されるように意図されている。 [0005] The detailed description set forth below in connection with the appended drawings is intended as a description of the presently preferred embodiments of the present invention, and is representative of the only forms in which the present invention may be constructed or utilized. Not intended. It should be understood that the same or equivalent function and composition can be achieved by different embodiments, which are also intended to be included within the spirit and scope of the present invention. .
[0006]本発明は、銀含有物質などの遷移金属および１種または複数の天然ハーブを使用して、病原体によって引き起こされるウイルス状態または障害を防止および／または処置するための方法および組成物を対象とする。一部の実施形態では、組成物は、酢をさらに含み得る。このような病原体によって引き起こされる疾患、障害、または状態としては、限定することなく、がん、疣贅、陰部疣贅、ヘルペス、帯状疱疹、性器ヘルペス、およびヒトパピローマウイルスによって引き起こされる感染症がある。 [0006] The present invention is directed to methods and compositions for preventing and / or treating viral conditions or disorders caused by pathogens using transition metals such as silver-containing materials and one or more natural herbs. I assume. In some embodiments, the composition may further comprise vinegar. Diseases, disorders, or conditions caused by such pathogens include, without limitation, cancer, warts, genital warts, herpes, shingles, genital herpes, and infections caused by human papilloma virus.
[0007]一実施形態は、治療有効量の銀含有物質および治療有効量の天然ハーブを含む、ウイルス状態を処置するための抗ウイルス性組成物である。一部の実施形態では、抗ウイルス性組成物は、治療有効量の酢をさらに含み得る。 [0007] One embodiment is an antiviral composition for treating a viral condition comprising a therapeutically effective amount of a silver-containing material and a therapeutically effective amount of a natural herb. In some embodiments, the antiviral composition may further comprise a therapeutically effective amount of vinegar.
[0008]銀含有物質は、コロイド銀、硝酸銀、他の銀担持材料もしくは副生成物、またはこれらの任意の組合せであり得る。銀含有物質は、全組成物のおよそ１重量％〜およそ７５重量％の量で存在し得る。別の実施形態では、このような銀含有物質の量は、組成物のおよそ１重量％〜およそ５０重量％であり得る。より典型的な実施形態では、銀含有物質の量は、組成物のおよそ１重量％〜およそ２５重量％であり得る。 [0008] The silver-containing material can be colloidal silver, silver nitrate, other silver support materials or byproducts, or any combination thereof. The silver-containing material may be present in an amount of about 1% to about 75% by weight of the total composition. In another embodiment, the amount of such silver-containing material may be from about 1% to about 50% by weight of the composition. In more typical embodiments, the amount of silver containing material may be from about 1% to about 25% by weight of the composition.
[0009]本願で使用する天然ハーブとしては、とりわけ、イチジク、未熟イチジク、およびイチジク乳液がある。天然ハーブは、例えば、限定することなく、例えば、任意の果実、種子、花、葉、幹、樹皮、油などを含めた、Ｒｕｔａｃｅａｅ科、例えば、Ｒｕｔａ属；Ｍｙｒｔａｃｅａｅ科、より具体的には、Ｍｅｌａｌｅｕｃａ属の常緑低木の任意およびすべての部分由来であり得る。代わりに、または前述のものと組み合わせて、天然ハーブは、任意の果実、種子、花、葉、幹、樹皮、油などを含めた、Ｍｏｒａｃｅａｅ科、例えば、Ｆｉｃｕｓ属の木質木（ｗｏｏｄｙ ｔｒｅｅ）、低木、およびつる植物；ヒノキ科Ｃｕｐｒｅｓｓａｃｅａｅ、例えば、Ｔｈｕｊａ属における常緑針葉樹；またはこれらの任意の組合せの任意およびすべての部分にも由来し得る。本組成物において使用され得るハーブの他の例としては、Ｒｕｔａｃｅａｅ科のＲｕｔａ Ｇｒａｖｅｏｌｅｎｓ、Ｍｙｒｔａｃｅａｅ科由来のティーツリー（Ｎａｒｒｏｗ−ｌｅａｖｅｄ Ｐａｐｅｒｂａｒｋ）、ティーツリー（Ｎａｒｒｏｗ−ｌｅａｖｅｄ Ｔｅａ−ｔｒｅｅ）、ティーツリー（Ｎａｒｒｏｗ−ｌｅａｖｅｄ Ｔｉ−ｔｒｅｅ）、もしくはティーツリー（Ｓｎｏｗ−ｉｎ−ｓｕｍｍｅｒ）としても公知のＭｅｌａｌｅｕｃａ Ａｌｔｅｒｎｉｆｏｌｉａ；Ｃｕｐｒｅｓｓａｃｅａｅ科由来のＴｈｕｊａ Ｏｃｃｉｄｅｎｔａｌｉｓ；またはＭｏｒａｃｅａｅ科由来のイチジク、未熟イチジク、もしくはイチジク乳液、あるいはこれらの任意の組合せの任意の果実、種子、花、葉、幹、樹皮、油などを含めたハーブの任意およびすべての部分がある。 [0009] Natural herbs for use herein include, among others, figs, immature figs, and fig milk. Natural herbs include, for example, without limitation, for example, any fruit, seeds, flowers, leaves, stems, barks, oils, etc., Rutaceae, such as Ruta; Myrtaceae, more specifically, It may be from any and all parts of the evergreen shrub of the genus Melaleuca. Alternatively, or in combination with the foregoing, natural herbs include any fruit, seeds, flowers, leaves, stems, barks, oils, etc., Moraceae family, eg, woody trees of the genus Ficus, It can also be derived from shrubs and vines; Cupressaceae Cupressaceae, eg, evergreen conifers in the genus Thuja; or any and all parts of any combination thereof. Other examples of herbs that may be used in the present composition include Ruta Graveolens of the Rutaceae family, Tea trees from the Myrtaceae family (Narrow-leaved Paperbark), Tea trees (Narrow-leaved Tea-tree), Tea trees (Narrow- melaleuca alternifolia also known as leaved Ti-tree), or tea tree (Snow-in-summer); Thuja Occidentalis from the Cupressaceae family; or figs from the Moraceae family, immature figs, or fig milks, or any combination thereof Optional fruits, seeds, flowers, leaves, stems, barks, oils etc. There are all the parts.
[0010]天然ハーブとして、Ｅｃｈｉｎａｃｅａ、Ａｌｌｉｕｍ ｓａｔｉｖｕｍ（ニンニク）、Ｇｌｙｃｙｒｒｈｉｚａ ｇｌａｂｒａ（甘草）、Ａｓｔｒａｇａｌｕｓ、Ｓｃｕｔｅｌｌａｒｉａ ｂａｉｃａｌｅｎｓｉｓ、Ｃｉｎｃｈｏｎａ ｂａｒｋ、Ｚｉｎｇｉｂｅｒ ｏｆｆｉｃｉｎａｌｅ（ショウガ）、グレープフルーツ種子エキス、Ｌｏｎｉｃｅｒａ ｊａｐｏｎｉｃａ（スイカズラ）、Ｏｌｅａ ｅｕｒｏｐｅａ（オリーブの葉）、Ｓａｍｂｕｃｕｓ ｎｉｇｒａ（ブラックエルダーベリー）、Ｒｕｄｂｅｃｋｉａ（ブラックアイドスーザンの根）、Ｆｏｒｓｙｔｈｉａ ｓｕｓｐｅｎｓａ（レンギョウ属）、Ｉｓａｔｉｓ ｔｉｎｃｔｏｒａ（イサチディス（ｉｓａｒｉｄｉｓ））、Ｌｏｍａｔｉｕｍ ｄｉｓｓｅｃｕｔｉｍ（レプトタエニア（ｌｅｐｔｏｔａｅｎｉａ））、およびＳｃｈｉｚａｎｄｒａ ｃｈｉｎｅｎｓｉｓ（シザンドラ）、Ｃｒｏｔｏｎ ｌｅｃｈｌｅｒｉ（ドラゴンズブラッド）、Ｈｙｄｒａｓｔｉｓ Ｃａｎａｄｅｎｓｉｓ（ヒドラスチス）、Ｊｕｎｉｐｅｒｕｓ（ジュニパー）、Ｍｅｌｉｓｓａ ｏｆｆｉｃｉｎａｌｉｓ（レモンバーム）、Ｌｅｎｔｉｎｕｓ ｅｄｏｄｅｓ（シイタケ）、およびＥｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｅｓ（ユーカリ）の任意およびすべての部分（任意の果実、種子、花、葉、幹、樹皮、油などを含む）を、限定することなく、含むように本明細書で定義される抗ウイルス性天然ハーブ（抗ウイルス性ハーブとも呼ばれる）を挙げることもできる。これらの抗ウイルス性天然ハーブは、感染症のさらなる蔓延を低減することによって、かつ／または感染症に対する免疫系の応答をブーストすることによって、これらの抗ウイルス性効果を生じさせる。 [0010] As natural herbs, Echinacea, Allium sativum (garlic), Glycyrrhiza glabra (licorice), Astragalus, Scutellaria baicalensis, Cinchona bark, Zingiber officinale (ginger), grapefruit seed extract, Lonicera japonica (Himmelon), Olea europa (olive european) Leaves), Sambucus nigra (Black Elder Berry), Rudbeckia (Black Eid susan roots), Forsythia suspensa (Forsythia), Isatis tinctora (Isatidis (isaridis)), Lomatium dissecutim (Leptus) Taenia (leptotaenia), and Schizandra chinensis (Sishandra), Croton lechleri (Dragons Blood), Hydrastis Canadensis (Hydrastis), Juniperus (Juniper), Melissa officinalis (Lemon balm), Lentinus edodes (Saitake), and Eucalyptus Anti-viral natural herb (anti-viral natural herb (anti-viral natural) as defined herein including, without limitation, any and all parts (including any fruits, seeds, flowers, leaves, stems, barks, oils etc) Mention may also be made of sexual herbs. These antiviral natural herbs produce their antiviral effects by reducing the further spread of the infection and / or by boosting the response of the immune system to the infection.
[0011]出願人は、このような天然ハーブおよび抗ウイルス性天然ハーブはそれら自体、もしあれば、抗ウイルス剤単独として非常に限定された有効性を有すると考える。しかし、抗ウイルス性天然ハーブを含めた天然ハーブと組み合わせた銀含有または銀担持物質、例えば、コロイド銀、硝酸銀、銀誘導体材料、またはこれらの組合せなどの投与は、大いに優れた効果を有すると思われ、その効果は、これらのコンポーネント単独のいずれかの有効性をはるかに超えて組成物の抗ウイルス性質の有効性を改善する。 [0011] Applicants believe that such natural herbs and antiviral natural herbs themselves have very limited efficacy as antiviral agents alone, if any. However, administration of a silver-containing or silver-bearing material, such as colloidal silver, silver nitrate, silver derivative materials, or a combination thereof, in combination with natural herbs, including antiviral natural herbs, is believed to have much better efficacy. The effect is to improve the efficacy of the antiviral properties of the composition far beyond the efficacy of any of these components alone.
[0012]抗ウイルス性ハーブまたは天然ハーブは、全組成物のおよそ２５重量％〜およそ９９重量％の間の量で存在し得る。好ましくは、抗ウイルス性天然ハーブまたは天然ハーブは、全組成物のおよそ５０重量％〜およそ９９重量％の間の量で存在する。より好ましくは、抗ウイルス性天然ハーブまたは天然ハーブは、全組成物のおよそ７５重量％〜およそ９９重量％の間の量で存在する。 [0012] The antiviral or natural herb may be present in an amount between about 25% and about 99% by weight of the total composition. Preferably, the antiviral natural herb or natural herb is present in an amount between about 50% and about 99% by weight of the total composition. More preferably, the antiviral natural herb or natural herb is present in an amount between about 75% and about 99% by weight of the total composition.
[0013]一部の実施形態では、本発明の抗ウイルス性組成物の有効性は、酢の添加でさらに改善され得る。酢は、ある特定の細菌によってエタノールを発酵させて酢酸にすることによって創製される。多くの異なるタイプの酢、例えば、アップルサイダー、バルサミコ、トウ、ココナツ、ナツメヤシ、蒸留、東アジア黒、果実、ハチミツ、ハトムギ、キーウィ、昆布茶、麦芽、パーム、ザクロ、レーズン、米、シェリー、スピリット、白、およびワイン酢などを使用することができる。好適な実施形態では、酢は、赤酢である。 [0013] In some embodiments, the efficacy of the antiviral composition of the present invention may be further improved with the addition of vinegar. Vinegar is created by fermenting ethanol into acetic acid by certain bacteria. Many different types of vinegar, such as apple cider, balsamic, tow, coconut, date palm, distilled, East Asia black, fruit, honey, stalk, kiwi, kelp tea, malt, palm, pomegranate, raisin, rice, sherry, spirit , White, and wine vinegar can be used. In a preferred embodiment, the vinegar is red vinegar.
[0014]酢は、組成物の総重量のおよそ５％〜およそ９０％の量で存在し得る。好ましくは、酢は、組成物のおよそ２５重量％〜およそ７５重量％の量で存在する。より好ましくは、酢は、組成物のおよそ３０重量％〜およそ４０重量％の量で存在し得る。 [0014] Vinegar may be present in an amount of about 5% to about 90% of the total weight of the composition. Preferably, vinegar is present in an amount of about 25% to about 75% by weight of the composition. More preferably, vinegar may be present in an amount of about 30% to about 40% by weight of the composition.
[0015]酢を含有する実施形態では、天然ハーブ（抗ウイルス性天然ハーブを含む）の量は、調整することができる。例えば、酢が組成物中に存在する場合、天然ハーブは、組成物のおよそ９重量％〜およそ９４重量％の量で存在し得る。好ましくは、ハーブは、組成物の２４重量％〜およそ７４重量％の量で存在し得る。より好ましくは、ハーブは、組成物の３５重量％〜およそ６９重量％の量で存在し得る。 [0015] In embodiments containing vinegar, the amount of natural herbs (including antiviral natural herbs) can be adjusted. For example, if vinegar is present in the composition, the natural herb may be present in an amount of about 9% to about 94% by weight of the composition. Preferably, the herb may be present in an amount of 24% to about 74% by weight of the composition. More preferably, the herb may be present in an amount of 35% to about 69% by weight of the composition.
[0016]本願の発明は、ウイルス状態を処置する方法であって、銀含有物質および天然ハーブを含む治療有効量の抗ウイルス性組成物を投与し、それによってウイルス状態が改善されるステップを含む、方法も対象とすることができる。一部の実施形態では、ウイルス状態を処置する方法は、銀含有物質、天然ハーブ、および酢を含む治療有効量の抗ウイルス性組成物を投与し、それによって状態が改善されるステップを含み得る。 [0016] The invention of the present application is a method of treating a viral condition, comprising administering a therapeutically effective amount of an antiviral composition comprising a silver-containing substance and a natural herb, whereby the viral condition is improved. , Methods can also be targeted. In some embodiments, the method of treating a viral condition may comprise the step of administering a therapeutically effective amount of an antiviral composition comprising a silver-containing material, a natural herb, and vinegar, whereby the condition is improved. .
[0017]投与ステップは、薬物送達の任意の方法、例えば、局所塗布、経口投与、パッチ塗布、リンス液、皮下注射などであり得る。最も典型的には、組成物は、局所塗布によって投与される。局所塗布には、皮膚の表面への組成物の投与をもたらす任意の塗布が含まれる。一般に、１滴または数滴（病変部のサイズに応じて）の組成物が、直径１ミリメートル以下の小さい処置範囲にとって十分である。好ましくは、十分な量の組成物が、任意の腫れ物、病変部、新生物、または腫瘍を十分に覆うように塗布されるべきである。 [0017] The administration step may be any method of drug delivery, such as topical application, oral administration, patch application, rinse, subcutaneous injection and the like. Most typically, the composition is administered by topical application. Topical application includes any application that results in the administration of the composition to the surface of the skin. In general, a composition of one or a few drops (depending on the size of the lesion) is sufficient for small treatment areas of 1 millimeter or less in diameter. Preferably, a sufficient amount of the composition should be applied to sufficiently cover any swelling, lesions, neoplasms or tumors.
[0018]局所的に投与される実施形態では、組成物は、クリーム、ゲル、軟膏、錠剤、カプセル剤、パッチなどをさらに含むことによって、活性成分と皮膚上の処置の箇所との間の接触を延長することができる。 [0018] In a topically administered embodiment, the composition further comprises a cream, a gel, an ointment, a tablet, a capsule, a patch, and the like to contact the active ingredient with the point of treatment on the skin. Can be extended.
[0019]多くの実施形態では、本発明の組成物は、１日おきに１回投与することができる。他の実施形態では、組成物は、週に１回以上投与することができる。さらに他の実施形態では、組成物は、１日に１回以上投与することができる。 [0019] In many embodiments, the compositions of the present invention can be administered once every other day. In another embodiment, the composition can be administered one or more times weekly. In still other embodiments, the composition can be administered one or more times daily.
[0020]男性の対象は、３０年にわたって足の裏で足底疣贅に罹患していた。疣贅を処置するための複数の試みは、失敗に終わった。対象を、全組成物の３０重量％の２００ｐｐｍ銀含有物質、および全組成物の７０重量％の未熟イチジクの組合せを含む組成物で処置した。対象を、４週間にわたって１週間に１回処置した。処置の４週間後に、足底疣贅は完全に消失しており、残留する疼痛がなく、灼熱感（ｂｕｒｎｉｎｇ）がなく、瘢痕がなく、開放創がなく、かつ最後に述べるが軽んじてはならないこととして、２年超後に再発することがなかった。他の処置では、正の結果が、３０重量％の３０ｐｐｍを含む他の濃度の銀含有物質でも見られた。 [0020] Male subjects have had plantar warts on the sole of the foot for 30 years. Several attempts to treat the wart ended in failure. The subject was treated with a composition comprising a combination of 30% by weight 200 ppm silver-containing material of the total composition, and 70% by weight immature figs of the total composition. Subjects were treated once a week for 4 weeks. After 4 weeks of treatment, the plantar warts have completely disappeared, there is no residual pain, no burning, no scars, no open wounds, and the last mention is mild. Not to mention, it did not recur after more than two years. With other treatments, positive results were also seen at other concentrations of silver-containing material, including 30 wt% of 30 ppm.
[0021]本発明を特定の実施形態に関して記載してきたが、本発明の追加の変形体を、本発明の概念から逸脱することなく案出することができることが認識される。 Although the invention has been described with respect to particular embodiments, it is recognized that additional variations of the invention can be devised without departing from the inventive concept.
Claims (20)
（ａ）治療有効量の銀含有物質、
（ｈ）治療有効量の天然ハーブ、および
（ｃ）赤酢
を含み、それを必要とする対象におけるウイルス状態の処置に適している、抗ウイルス性組成物。 An antiviral composition for treating a viral condition, comprising
(A) a therapeutically effective amount of a silver-containing substance,
An antiviral composition comprising (h) a therapeutically effective amount of a natural herb, and (c) red vinegar, which is suitable for the treatment of a viral condition in a subject in need thereof.
（ａ）疣贅
（ｂ）陰部疣贅、および
（ｃ）ヒトパピローマウイルスによって引き起こされる疾患
からなる群から選択される、請求項６に記載の抗ウイルス性組成物。 The antiviral status is
The antiviral composition according to claim 6, which is selected from the group consisting of (a) warts (b) genital warts and (c) diseases caused by human papilloma virus.
（ａ）Ｒｕｔａｃｅａｅハーブ、
（ｂ）Ｍｙｒｔａｃｅａｅハーブ、
（ｃ）Ｃｕｐｒｅｓｓａｃｅａｅハーブ、
（ｄ）Ｍｏｒａｃｅａｅハーブ、および
（ｅ）抗ウイルス性天然ハーブ
からなる群から選択される、請求項１に記載の抗ウイルス性組成物。 Natural herbs,
(A) Rutaceae herbs,
(B) Myrtaceae herbs,
(C) Cupressaceae herbs,
The antiviral composition according to claim 1, wherein the antiviral composition is selected from the group consisting of (d) Morese herb and (e) antiviral natural herb.
（ａ）Ｒｕｔａ Ｇｒａｖｅｏｌｅｎｓ、
（ｂ）Ｍｅｌａｌｅｕｃａ Ａｌｔｅｒｎｉｆｏｌｉａ、
（ｃ）Ｔｈｕｊａ Ｏｃｃｉｄｅｎｔａｌｉｓ、
からなる群から選択される、請求項１に記載の抗ウイルス性組成物。 Natural herbs,
(A) Ruta Graveolens,
(B) Melaleuca Alternifolia,
(C) Thuja Occidentalis,
The antiviral composition according to claim 1, which is selected from the group consisting of
（ａ）イチジク、
（ｂ）未熟イチジク、および
（ｃ）イチジク乳液
からなる群から選択される、請求項１に記載の抗ウイルス性組成物。 Natural herbs,
(A) Fig,
The antiviral composition according to claim 1, which is selected from the group consisting of (b) immature figs and (c) fig milk.
（ａ）疣贅、
（ｂ）陰部疣贅、および
（ｃ）ヒトパピローマウイルスによって引き起こされる疾患
からなる群から選択される、請求項１に記載の抗ウイルス性組成物。 The antiviral status is
(A) warts,
The antiviral composition according to claim 1, which is selected from the group consisting of (b) genital warts and (c) diseases caused by human papilloma virus.
（ａ）疣贅、
（ｂ）陰部疣贅、および
（ｃ）ヒトパピローマウイルスによって引き起こされる疾患
からなる群から選択される、請求項１９に記載の方法。 The antiviral status is
(A) warts,
20. The method of claim 19, wherein the method is selected from the group consisting of (b) genital warts and (c) diseases caused by human papilloma virus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/030472 WO2018203879A1 (en) | 2017-05-01 | 2017-05-01 | Anti-viral compositions and method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020131512A Division JP2020186253A (en) | 2020-08-03 | 2020-08-03 | Anti-viral composition and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2019515870A true JP2019515870A (en) | 2019-06-13 |
Family
ID=64016317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541381A Pending JP2019515870A (en) | 2017-05-01 | 2017-05-01 | Antiviral compositions and methods |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3600555A4 (en) |
| JP (1) | JP2019515870A (en) |
| CN (1) | CN110740785A (en) |
| WO (1) | WO2018203879A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020186253A (en) * | 2020-08-03 | 2020-11-19 | イラジ・イー・キアニ | Anti-viral composition and method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4304621A4 (en) * | 2021-03-10 | 2024-06-26 | Wahi Pharmaceuticals Inc. | HERBAL EXTRACT FORMULA FOR TREATMENT OF CORONAVIRUS INFECTION |
| JP6973835B1 (en) * | 2021-03-19 | 2021-12-01 | 株式会社Ｙｏｏコーポレーション | Antiviral agent |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004059463A (en) * | 2002-07-26 | 2004-02-26 | Lotte Co Ltd | Anti-influenza virus agent and composition containing the same and food or drink |
| US20110104302A1 (en) * | 2007-07-18 | 2011-05-05 | Kiani Iraj E | Composition and method for treating viral conditions |
| JP2013537196A (en) * | 2010-09-10 | 2013-09-30 | ザ プロクター アンド ギャンブル カンパニー | Cosmetic composition containing ficus serum fraction and method for reducing the occurrence of excessive pigmentation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012101A (en) * | 1999-12-20 | 2001-07-03 | New Pharma Research Sweden Ab | Veterinary compositions |
| US7850998B2 (en) * | 2007-07-18 | 2010-12-14 | Kiani Iraj E | Method of treating viral conditions |
| US7700137B1 (en) * | 2007-07-18 | 2010-04-20 | Kiani Iraj E | Anti-viral compositions and method |
| CN107951972A (en) * | 2017-11-27 | 2018-04-24 | 青岛农业大学 | Apply medicinal lotion or ointment outside a kind of Chinese traditional medicine composition for treating mastitis for milk cows thing and preparation method thereof |
-
2017
- 2017-05-01 WO PCT/US2017/030472 patent/WO2018203879A1/en not_active Ceased
- 2017-05-01 JP JP2017541381A patent/JP2019515870A/en active Pending
- 2017-05-01 CN CN201780091578.4A patent/CN110740785A/en active Pending
- 2017-05-01 EP EP17908500.6A patent/EP3600555A4/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004059463A (en) * | 2002-07-26 | 2004-02-26 | Lotte Co Ltd | Anti-influenza virus agent and composition containing the same and food or drink |
| US20110104302A1 (en) * | 2007-07-18 | 2011-05-05 | Kiani Iraj E | Composition and method for treating viral conditions |
| JP2013537196A (en) * | 2010-09-10 | 2013-09-30 | ザ プロクター アンド ギャンブル カンパニー | Cosmetic composition containing ficus serum fraction and method for reducing the occurrence of excessive pigmentation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020186253A (en) * | 2020-08-03 | 2020-11-19 | イラジ・イー・キアニ | Anti-viral composition and method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110740785A (en) | 2020-01-31 |
| WO2018203879A1 (en) | 2018-11-08 |
| EP3600555A4 (en) | 2020-10-28 |
| EP3600555A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rajvaidhya et al. | A review on Acacia Arabica-an Indian medicinal plant | |
| Bhowmik et al. | Recent trends in Indian traditional herbs Syzygium aromaticum and its health benefits | |
| Morton | Folk uses and commercial exploitation of Aloe leaf pulp | |
| US20100303935A1 (en) | Medicinal Composition | |
| JP2008534675A (en) | Antibacterial composition containing natural extract, nanosilver, and natural essential oil | |
| US7850998B2 (en) | Method of treating viral conditions | |
| US7842317B2 (en) | Method of treating viral conditions | |
| Chandra et al. | An industrial cultivation of Tulsi (Ocimum sanctum) for medicinal use and rural empowerment | |
| Kaur et al. | An overview of Tulsi (Holy basil) | |
| Osuntokun | Efficacy, properties and therapeutic use of some major medicinal plants for human health | |
| US8637094B2 (en) | Composition and method for treating viral conditions | |
| JP2019515870A (en) | Antiviral compositions and methods | |
| Abou Auda | An updated comprehensive review, systematics and biological activity of medicinal plants used in traditional medicines and their common uses in the Gaza Strip | |
| US20100068306A1 (en) | Compositions for accelerating the healing response | |
| CN116210732B (en) | Preparation method and application of a mite-removing and odor-removing plant extract combination liquid | |
| Otimanam et al. | Cutaneous wound healing activity of herbal ointment containing Tetrapleura tetraptera fruit extract | |
| JP2020186253A (en) | Anti-viral composition and method | |
| Barkwell | La michinn: Traditional Métis medicine and healing | |
| Erhabor et al. | Croton gratissimus Burch.(Lavender croton): A Review of the Traditional Uses, Phytochemistry, Nutritional Constituents and Pharmacological Activities. | |
| Goswami et al. | A Critical Review on Traditional Herbal Plant ‘Tulsi’ | |
| Ferrara | Phytotherapy as a preventive and adjuvant for the rhinitis | |
| Razzaq et al. | An Ethnobotanical Servey of Pakistani Medicinal Plants and Their Future In Pharmaceuticals Development | |
| Sharma et al. | A Comprehensive Analysis of the Therapeutic Efficacy of Sida Genus | |
| Lule | Evaluation of the Opportunities of Medical Plants in the Treatment of Diseases | |
| Shere et al. | PHARMACOLOGICAL ACTIVITIES OF OCIMUM SANCTUM (TULSI): A REVIEW |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190827 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200403 |